Suresh S. Ramalingam, MD

P6823488

Specialty

Nationally recognized for his research, Dr. Ramalingam has developed individualized therapies for patients with small cell and non-small cell lung cancer.

Titles and Roles

Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Roberto C. Goizueta Distinguished Chair for Cancer Research
Emory University School of Medicine
Deputy Director
Winship Cancer Institute of Emory University
Assistant Dean for Cancer Research
Emory University School of Medicine
Director, Division of Medical Oncology, Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Lung Cancer Program
Winship Cancer Institute of Emory University
Co-Leader, Discovery & Developmental Therapeutics Program
Winship Cancer Institute of Emory University
Medical Oncologist
Lung Cancer
Phase I Clinical Trials Unit
Research Program
Discovery and Developmental Therapeutics

Biography

Suresh S. Ramalingam, MD, is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology and is an active member of American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association of Lung Cancer Study. Dr. Ramalingam plays an active role in the Eastern Cooperative Oncology Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair for Therapeutics Program.

Dr. Ramalingam serves on several international, national and Institutional Committees. He is currently a recipient of peer-reviewed grants from the National Cancer Institute.

Education

Dr. Ramalingam is a graduate of Kilpauk Medical College at the University of Madras in Madras, India. He completed his residency in internal medicine at Wayne State University in Detroit, Michigan, and his fellowship in hematology and medical oncology at the University of Pittsburgh Cancer Institute in Pittsburgh, Pennsylvania.

Research

Dr. Ramalingam's present research involves developing immune checkpoint inhibitors and improving outcomes for patients with EGFR mutation. He has conducted several phase 1, 2 and 3 clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer.

  • Below is a listing of current federal grants for the above principal investigator.

    GrantNumberTitle

Publications

Dr. Ramalingam has authored over 200 scientific publications and is the section editor for "Chest Diseases" for the journal Cancer. He is on the editorial boards of the Journal of Clinical Oncology, Annals of Oncology, and Clinical Lung Cancer.

  • PublicationsPublication Date

Awards

Dr. Ramalingam is the recipient of several awards including the James Eckman Award for Excellence in Teaching at Emory, ECOG-ACRIN Young Investigator Award, and the NCI Cancer Clinical Investigator Team Leadership Award. He was named a Georgia Cancer Coalition Distinguished Cancer Scholar in 2008.

Cascade Link   TOP